Major study launches to track safety of new diabetes 'Artificial Pancreas' system
NCT ID NCT07356089
Summary
This study aims to collect real-world safety data on the Twiist automated insulin delivery system, which is designed to help manage type 1 diabetes. It will follow 1,875 adults and children in the U.S. who are already using the Twiist system for 12 months. The main goal is to track serious low and high blood sugar events, hospitalizations, and other safety issues to understand how the device performs in everyday life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jaeb Center for Health Research
RECRUITINGTampa, Florida, 33647, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.